drugset / Trial / NCT05901051
High-dose Dual Therapy with Different Administration Frequencies
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a single center, randomized controlled clinical study. The enrolled patients are HP positive. They are diagnosed as HP positive by rapid urease test and/or 13C urea breath test. According to the declaration of Helsinki, 327 patients will be included in this study. After obtaining the written informed consent of the patients, HP culture and drug sensitivity test will be conducted on all the selected patients with the success rate, adverse reactions, compliance, antibiotic resistance of HP and its impact on HP eradication.
Timeline
- Start
- 2021-03-30
- Primary completion
- 2023-09-10
- Completion
- 2023-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 0.75 g | — |
| Subject | Amoxicillin | Other / unclassified | 1 g | — |
| Background | Vonoprazan | Other / unclassified | 20 mg | — |